ArticleMaterials today. Bio2026
Bioenergetic-active hybrid nanovesicles empower tumor associated macrophages phagocytosis for cancer immunotherapy.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bioenergy critically empowers cytoskeletal remodeling, which is essential for tumor-associated macrophages (TAMs) to engulf cancer cells. Consequently, engineering a bioenergetic-active nanomaterial to enhance TAM phagocytosis represents a promising strategy for cancer immunotherapy. Here, we develop a hybrid membrane-derived biomimetic nanovesicle loaded with paeonol (PAE) liposomes that exhibits capabilities for bioenergetic activation, TAM reprogramming, and TAM targeting. This nanovesicle, named PAE@mBG, utilizes bacterial ghosts (BGs) as a key component of its shell structure. BGs not only repolarize M2-like TAMs to the M1-like phenotype via their pathogen-associated molecular patterns, but also provide a hollow structure for efficient PAE loading. The PAE in PAE@mBG inhibits the AKT/mTOR pathway to induce mitophagy, thus enhancing ATP levels. This elevated ATP promotes F-actin polymerization and cytoskeletal remodeling, as evidenced by increased F-actin intensity and filament length, ultimately improving TAM phagocytosis. Furthermore, PAE@mBG efficiently targets TAMs through its hybrid membrane, which integrates BGs with M2pep-peptide-modified macrophage membranes possessing capabilities of innate tumor-homing and specific M2 macrophage targeting. Our findings demonstrate that PAE@mBG efficiently targets TAMs and enhances phagocytosis through bioenergetic activation and M2-to-M1 phenotype reprogramming, thereby triggering both innate and adaptive immunity for lung cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.